Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
60.60
-0.08 (-0.13%)
At close: Mar 28, 2025, 4:00 PM
60.64
+0.04 (0.06%)
After-hours: Mar 28, 2025, 7:57 PM EDT
Incyte Employees
Incyte had 2,617 employees as of December 31, 2024. The number of employees increased by 93 or 3.68% compared to the previous year.
Employees
2,617
Change (1Y)
93
Growth (1Y)
3.68%
Revenue / Employee
$1,620,641
Profits / Employee
$12,463
Market Cap
11.73B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2,617 | 93 | 3.68% |
Dec 31, 2023 | 2,524 | 200 | 8.61% |
Dec 31, 2022 | 2,324 | 230 | 10.98% |
Dec 31, 2021 | 2,094 | 321 | 18.10% |
Dec 31, 2020 | 1,773 | 317 | 21.77% |
Dec 31, 2019 | 1,456 | 89 | 6.51% |
Dec 31, 2018 | 1,367 | 159 | 13.16% |
Dec 31, 2017 | 1,208 | 228 | 23.27% |
Dec 31, 2016 | 980 | 288 | 41.62% |
Dec 31, 2015 | 692 | 104 | 17.69% |
Dec 31, 2014 | 588 | 107 | 22.25% |
Dec 31, 2013 | 481 | 68 | 16.46% |
Dec 31, 2012 | 413 | 45 | 12.23% |
Dec 31, 2011 | 368 | 121 | 48.99% |
Dec 31, 2010 | 247 | 26 | 11.76% |
Dec 31, 2009 | 221 | 9 | 4.25% |
Dec 31, 2008 | 212 | 16 | 8.16% |
Dec 31, 2007 | 196 | 10 | 5.38% |
Dec 31, 2006 | 186 | 9 | 5.08% |
Dec 31, 2005 | 177 | -9 | -4.84% |
Dec 31, 2004 | 186 | -268 | -59.03% |
Dec 31, 2003 | 454 | -37 | -7.54% |
Dec 31, 2002 | 491 | -94 | -16.07% |
Dec 31, 2001 | 585 | -737 | -55.75% |
Dec 31, 2000 | 1,322 | 214 | 19.31% |
Dec 31, 1999 | 1,108 | 241 | 27.80% |
Dec 31, 1998 | 867 | 191 | 28.25% |
Dec 31, 1997 | 676 | 218 | 47.60% |
Dec 31, 1996 | 458 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
INCY News
- 3 days ago - Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico - GlobeNewsWire
- 10 days ago - Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib - Seeking Alpha
- 11 days ago - Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results - Investopedia
- 11 days ago - Incyte Is Today's Worst S&P 500 Stock. Here's Why. - Barrons
- 11 days ago - Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls - Benzinga
- 11 days ago - Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 12 days ago - Incyte's skin disease drug meets main goal in two late-stage studies - Reuters
- 12 days ago - Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa - Business Wire